CTX 10726
Alternative Names: CTX-10726Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator Compass Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Jan 2025 Preclinical trials in Solid tumours in USA (Parenteral), prior to January 2025
- 08 Jan 2025 Compass Therapeutics announces intention to submit IND for Solid tumours, in the fourth quarter of 2025
- 08 Jan 2025 Pharmacodynamics data from preclinical trials in Solid tumours released by Compass Therapeutics